Bellerophon Therapeutics Inc. (BLPH) NASDAQ
$0.92 0.02 (2.22%)
Market Cap: $8.78M
As of 06/24/22 04:00 PM EDT. Market closed.
Bellerophon Therapeutics Inc. (BLPH) NASDAQ
$0.92 0.02 (2.22%)
Market Cap: $8.78M
As of 06/24/22 04:00 PM EDT. Market closed.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery ... read more
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. read less
COMPANY PROFILE
Sector
Industry
CEO
Fabian Tenenbaum
Full Time Employees
21
Sector
Industry
CEO
Fabian Tenenbaum
Full Time Employees
21
URL
Address
184 Liberty Corner Rd Ste 302, New Jersey, Warren, 07059-6868.
PRICE CHART
From:
To:
NEWS
KEY STATS
Open
$1.17
Previous Close
$0.90
Days Range
$0.84 - $1.28
52 week range
$0.67 - $5.75
Volume
602,476
Avg. Volume (30 days)
48,912
Market Cap
$8.78M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
9,545,451
Open
$1.17
Previous Close
$0.90
Days Range
$0.84 - $1.28
52 week range
$0.67 - $5.75
Volume
602,476
Avg. Volume (30 days)
48,912
Market Cap
$8.78M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
9,545,451
Open in:
Open in:
INSIDER TRANSACTIONS FOR BELLEROPHON THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Puissance Life Science Opportunities Fund VI | 10% Owner | Jun 07, 2021 | Option Exercise | $4.00 | 8,189 | 32,756 | 1,771,262 | Jun 08, 2021, 12:37 PM |
| New Mountain Investments II, LLC | 10% Owner | Mar 18, 2021 | Sale | $5.48 | 400,000 | 2,192,000 | 609,231 | Mar 22, 2021, 09:36 PM |
| FARES Wassim | Chief Medical Officer | Sep 10, 2020 | Buy | $10.18 | 4,000 | 40,708 | 4,000 | Sep 14, 2020, 08:31 AM |
| Wang Theodore T | Director | Jun 08, 2020 | Buy | $12.87 | 2,600 | 33,454 | 60,913 | Jun 09, 2020, 04:01 PM |
| Wang Theodore T | Director | Jun 05, 2020 | Buy | $12.72 | 4,986 | 63,442 | 58,313 | Jun 09, 2020, 04:01 PM |
| Puissance Life Science Opportunities Fund VI | 10% Owner | May 21, 2020 | Option Exercise | $13.00 | 1,153,846 | 14,999,998 | 1,153,846 | May 22, 2020, 07:25 AM |
| Wang Theodore T | Director | Nov 25, 2019 | Buy | $0.39 | 7,193 | 2,774 | 592,922 | Nov 25, 2019, 04:52 PM |
| Wang Theodore T | Director | Nov 22, 2019 | Buy | $0.37 | 1,050 | 394 | 585,729 | Nov 25, 2019, 04:52 PM |
| Wang Theodore T | Director | Nov 21, 2019 | Buy | $0.37 | 200 | 74 | 584,679 | Nov 25, 2019, 04:52 PM |
| Shah Parag Suresh | VP of Business Operations | Nov 15, 2019 | Option Exercise | $0.34 | 25,993 | 8,838 | 105,606 | Nov 19, 2019, 04:36 PM |
| Fernandes Peter | Chief Regulatory & Safety Offr | Nov 15, 2019 | Option Exercise | $0.34 | 40,280 | 13,695 | 182,022 | Nov 19, 2019, 04:36 PM |
| Tenenbaum Fabian | Chief Executive Officer | Nov 15, 2019 | Option Exercise | $0.34 | 76,823 | 26,120 | 407,459 | Nov 19, 2019, 04:36 PM |
| Dekker Martin | VP of Engineering & Manuf | Nov 15, 2019 | Option Exercise | $0.34 | 27,134 | 9,226 | 124,619 | Nov 19, 2019, 04:35 PM |
| Korner Assaf | CFO | Nov 15, 2019 | Option Exercise | $0.34 | 32,987 | 11,216 | 66,078 | Nov 19, 2019, 04:35 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 28, 2019 | Sale | $0.44 | 333,010 | 146,091 | 6,435,173 | Oct 28, 2019, 05:17 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 25, 2019 | Sale | $0.45 | 56,242 | 25,511 | 6,768,183 | Oct 28, 2019, 05:17 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 24, 2019 | Sale | $0.50 | 704,595 | 353,354 | 6,824,425 | Oct 28, 2019, 05:17 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 28, 2019 | Sale | $0.44 | 333,010 | 146,091 | 6,435,173 | Oct 28, 2019, 05:15 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 25, 2019 | Sale | $0.45 | 56,242 | 25,511 | 6,768,183 | Oct 28, 2019, 05:15 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Oct 24, 2019 | Sale | $0.50 | 704,595 | 353,354 | 6,824,425 | Oct 28, 2019, 05:15 PM |
| Wang Theodore T | Director | Jun 12, 2019 | Buy | $0.64 | 50,000 | 31,905 | 584,479 | Jun 14, 2019, 11:46 AM |
| Wang Theodore T | Director | May 22, 2019 | Buy | $0.60 | 27,500 | 16,533 | 534,479 | May 24, 2019, 09:30 AM |
| Edmonds Amy | VP Clinical Operations & Admin | May 22, 2019 | Option Exercise | $0.61 | 35,827 | 21,797 | 140,216 | May 23, 2019, 04:46 PM |
| Wang Theodore T | Director | May 21, 2019 | Buy | $0.61 | 43,280 | 26,371 | 506,979 | May 22, 2019, 11:15 AM |
| Peacock Jonathan M | Director | May 21, 2019 | Buy | $0.61 | 20,000 | 12,198 | 1,875,920 | May 22, 2019, 11:14 AM |
| Tenenbaum Fabian | Chief Executive Officer | May 21, 2019 | Buy | $0.60 | 5,000 | 2,975 | 484,282 | May 22, 2019, 11:14 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Jan 23, 2019 | Buy | $0.70 | 142,857 | 100,000 | 7,529,020 | Mar 14, 2019, 05:57 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Jan 23, 2019 | Buy | $0.70 | 142,857 | 100,000 | 7,529,020 | Mar 14, 2019, 05:51 PM |
| Wang Theodore T | Director | Jan 25, 2019 | Buy | $0.70 | 450,000 | 315,000 | 463,699 | Jan 25, 2019, 04:22 PM |
| Peacock Jonathan M | Director | Jan 25, 2019 | Buy | $0.70 | 714,286 | 500,000 | 1,855,920 | Jan 25, 2019, 04:21 PM |
| Amin Naseem | Director | Jan 25, 2019 | Buy | $0.70 | 571,429 | 400,000 | 1,818,867 | Jan 25, 2019, 04:12 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 13, 2018 | Buy | $1.19 | 75,000 | 89,160 | 7,251,163 | Sep 17, 2018, 04:46 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 17, 2018 | Buy | $1.18 | 60,000 | 70,944 | 7,386,163 | Sep 17, 2018, 04:46 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 14, 2018 | Buy | $1.23 | 75,000 | 92,250 | 7,326,163 | Sep 17, 2018, 04:46 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 17, 2018 | Buy | $1.18 | 60,000 | 70,944 | 7,386,163 | Sep 17, 2018, 04:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 14, 2018 | Buy | $1.23 | 75,000 | 92,250 | 7,326,163 | Sep 17, 2018, 04:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 13, 2018 | Buy | $1.19 | 75,000 | 89,160 | 7,251,163 | Sep 17, 2018, 04:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 11, 2018 | Buy | $1.14 | 200,000 | 228,840 | 7,101,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 10, 2018 | Buy | $1.22 | 200,000 | 243,640 | 6,901,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 12, 2018 | Buy | $1.15 | 75,000 | 85,912 | 7,176,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 11, 2018 | Buy | $1.14 | 200,000 | 228,840 | 7,101,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 10, 2018 | Buy | $1.22 | 200,000 | 243,640 | 6,901,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 12, 2018 | Buy | $1.15 | 75,000 | 85,912 | 7,176,163 | Sep 12, 2018, 12:00 AM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 06, 2018 | Buy | $0.84 | 50,000 | 42,095 | 6,641,163 | Sep 07, 2018, 05:45 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 05, 2018 | Buy | $0.85 | 50,000 | 42,325 | 6,591,163 | Sep 07, 2018, 05:45 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 07, 2018 | Buy | $0.90 | 60,000 | 53,742 | 6,701,163 | Sep 07, 2018, 05:45 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 07, 2018 | Buy | $0.90 | 60,000 | 53,742 | 6,701,163 | Sep 07, 2018, 05:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 06, 2018 | Buy | $0.84 | 50,000 | 42,095 | 6,641,163 | Sep 07, 2018, 05:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Sep 05, 2018 | Buy | $0.85 | 50,000 | 42,325 | 6,591,163 | Sep 07, 2018, 05:42 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 16, 2018 | Buy | $0.65 | 66,393 | 43,109 | 6,541,163 | Aug 16, 2018, 07:33 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 15, 2018 | Buy | $0.65 | 272,000 | 175,902 | 6,474,770 | Aug 16, 2018, 07:33 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 14, 2018 | Buy | $0.65 | 190,977 | 123,868 | 6,202,770 | Aug 16, 2018, 07:33 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 14, 2018 | Buy | $0.65 | 190,977 | 123,868 | 6,202,770 | Aug 16, 2018, 07:31 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 16, 2018 | Buy | $0.65 | 66,393 | 43,109 | 6,541,163 | Aug 16, 2018, 07:31 PM |
| VENROCK ASSOCIATES IV L P | 10% Owner | Aug 15, 2018 | Buy | $0.65 | 272,000 | 175,902 | 6,474,770 | Aug 16, 2018, 07:31 PM |
| Quinn Deborah | Chief Medical Officer | Jun 12, 2018 | Option Exercise | $2.37 | 10,541 | 24,982 | 94,070 | Jun 14, 2018, 04:42 PM |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | Jun 12, 2018 | Option Exercise | $2.37 | 7,144 | 16,931 | 53,094 | Jun 14, 2018, 04:41 PM |
| Edmonds Amy | VP Clinical Operations & Admin | Jun 12, 2018 | Option Exercise | $2.37 | 7,499 | 17,773 | 93,800 | Jun 14, 2018, 04:40 PM |
| Tenenbaum Fabian | Chief Executive Officer | Jun 12, 2018 | Option Exercise | $2.37 | 63,486 | 150,462 | 254,983 | Jun 14, 2018, 04:39 PM |
| Fernandes Peter | Chief Regulatory & Safety Offr | Jun 12, 2018 | Option Exercise | $2.37 | 11,304 | 26,790 | 102,676 | Jun 14, 2018, 04:37 PM |
| Dekker Martin | VP of Engineering & Manuf | Jun 12, 2018 | Option Exercise | $2.37 | 7,473 | 17,711 | 69,510 | Jun 14, 2018, 04:35 PM |
| Fernandes Peter | Chief Regulatory & Safety Offr | Jan 04, 2018 | Option Exercise | $2.49 | 35,321 | 87,949 | 82,453 | Jan 08, 2018, 05:26 PM |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | Jan 04, 2018 | Option Exercise | $2.49 | 23,180 | 57,718 | 39,548 | Jan 08, 2018, 04:52 PM |
| Dekker Martin | VP of Engineering & Manuf | Jan 04, 2018 | Option Exercise | $2.49 | 24,284 | 60,467 | 55,308 | Jan 08, 2018, 04:49 PM |
| Quinn Deborah | Chief Medical Officer | Jan 04, 2018 | Option Exercise | $2.49 | 33,114 | 82,454 | 75,054 | Jan 08, 2018, 04:46 PM |
| Schoeps Megan | Principal Financial Officer | Dec 13, 2017 | Option Exercise | $0.49 | 1,000 | 490 | 19,248 | Dec 13, 2017, 04:36 PM |
| Schoeps Megan | Principal Financial Officer | May 17, 2017 | Option Exercise | $1.40 | 10,459 | 14,683 | 18,248 | May 19, 2017, 04:04 PM |
| Luehring Jens | Director | Dec 09, 2016 | Buy | $0.56 | 20,000 | 11,200 | 39,860 | Dec 12, 2016, 10:10 AM |
| Quinn Deborah | Chief Medical Officer | Sep 12, 2016 | Option Exercise | $1.38 | 18,548 | 25,596 | 31,244 | Sep 13, 2016, 08:21 PM |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | Sep 12, 2016 | Option Exercise | $1.38 | 4,673 | 6,449 | 8,881 | Sep 13, 2016, 08:18 PM |
| Dekker Martin | VP of Device Engineering | Sep 12, 2016 | Option Exercise | $1.38 | 13,333 | 18,400 | 23,181 | Sep 13, 2016, 08:16 PM |
| Edmonds Amy | VP Clinical Operations & Admin | Sep 12, 2016 | Option Exercise | $1.38 | 13,301 | 18,355 | 23,213 | Sep 13, 2016, 08:14 PM |
| Fernandes Peter | Chief Regulatory Officer | Sep 12, 2016 | Option Exercise | $1.38 | 19,785 | 27,303 | 35,722 | Sep 13, 2016, 08:11 PM |
| Peacock Jonathan M | President and CEO | May 17, 2016 | Buy | $1.37 | 5,000 | 6,841 | 222,702 | May 18, 2016, 01:46 PM |
| Peacock Jonathan M | President and CEO | Dec 15, 2015 | Buy | $2.72 | 7,500 | 20,400 | 38,927 | Dec 17, 2015, 05:01 PM |
| Peacock Jonathan M | President and CEO | Dec 16, 2015 | Buy | $2.76 | 12,800 | 35,336 | 51,727 | Dec 17, 2015, 05:01 PM |
| Peacock Jonathan M | President and CEO | Aug 19, 2015 | Buy | $5.48 | 5,000 | 27,377 | 31,427 | Aug 20, 2015, 05:34 PM |
| MEGLASSON MARTIN | Chief Scientific Officer | May 20, 2015 | Buy | $8.40 | 712 | 5,981 | 19,098 | May 22, 2015, 07:32 AM |
| Peacock Jonathan M | President and CEO | May 20, 2015 | Buy | $8.69 | 5,560 | 48,323 | 26,427 | May 22, 2015, 07:32 AM |
| ARCH VENTURE FUND VI LP | 10% Owner | Feb 19, 2015 | Buy | $12.00 | 212,666 | 2,551,992 | 965,660 | Feb 23, 2015, 09:48 PM |
| NELSEN ROBERT | Director | Feb 19, 2015 | Buy | $12.00 | 212,666 | 2,551,992 | 965,660 | Feb 23, 2015, 09:47 PM |
| New Mountain Investments II, LLC | 10% Owner | Feb 19, 2015 | Buy | $12.00 | 1,070,166 | 12,841,992 | 4,859,885 | Feb 23, 2015, 09:47 PM |
| Weinstein Adam | Director | Feb 19, 2015 | Buy | $12.00 | 1,070,166 | 12,841,992 | 4,859,885 | Feb 23, 2015, 09:47 PM |
| Holt Matthew S. | Director | Feb 19, 2015 | Buy | $12.00 | 1,070,166 | 12,841,992 | 4,859,885 | Feb 23, 2015, 09:46 PM |
| Linde North America, Inc. | 10% Owner | Feb 19, 2015 | Buy | $12.00 | 358,916 | 4,306,992 | 1,629,804 | Feb 23, 2015, 09:41 PM |
| Luehring Jens | Director | Feb 19, 2015 | Buy | $12.00 | 358,916 | 4,306,992 | 1,629,804 | Feb 23, 2015, 09:41 PM |
| Tasse Daniel | Director | Feb 19, 2015 | Buy | $12.00 | 25,000 | 300,000 | 128,898 | Feb 23, 2015, 09:41 PM |
| Heyrman Reinilde | Chief Clinical Dev. Officer | Feb 19, 2015 | Buy | $12.00 | 1,500 | 18,000 | 9,483 | Feb 23, 2015, 09:40 PM |
| MEGLASSON MARTIN | Chief Scientific Officer | Feb 19, 2015 | Buy | $12.00 | 12,000 | 144,000 | 18,386 | Feb 23, 2015, 09:39 PM |
| Naidu Manesh | Chief Business Officer | Feb 19, 2015 | Buy | $12.00 | 1,500 | 18,000 | 11,319 | Feb 23, 2015, 09:39 PM |
| Peacock Jonathan M | President and CEO | Feb 19, 2015 | Buy | $12.00 | 20,800 | 249,600 | 20,867 | Feb 23, 2015, 09:39 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Puissance Life Science Opportunities Fund VI | 10% Owner | 06/07/2021 | 32,756 |
| New Mountain Investments II, LLC | 10% Owner | 03/18/2021 | 2,192,000 |
| FARES Wassim | Chief Medical Officer | 09/10/2020 | 40,708 |
| Wang Theodore T | Director | 06/08/2020 | 33,454 |
| Wang Theodore T | Director | 06/05/2020 | 63,442 |
| Puissance Life Science Opportunities Fund VI | 10% Owner | 05/21/2020 | 14,999,998 |
| Wang Theodore T | Director | 11/25/2019 | 2,774 |
| Wang Theodore T | Director | 11/22/2019 | 394 |
| Wang Theodore T | Director | 11/21/2019 | 74 |
| Shah Parag Suresh | VP of Business Operations | 11/15/2019 | 8,838 |
| Fernandes Peter | Chief Regulatory & Safety Offr | 11/15/2019 | 13,695 |
| Tenenbaum Fabian | Chief Executive Officer | 11/15/2019 | 26,120 |
| Dekker Martin | VP of Engineering & Manuf | 11/15/2019 | 9,226 |
| Korner Assaf | CFO | 11/15/2019 | 11,216 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 10/28/2019 | 146,091 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 10/25/2019 | 25,511 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 10/24/2019 | 353,354 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 10/28/2019 | 146,091 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 10/25/2019 | 25,511 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 10/24/2019 | 353,354 |
| Wang Theodore T | Director | 06/12/2019 | 31,905 |
| Wang Theodore T | Director | 05/22/2019 | 16,533 |
| Edmonds Amy | VP Clinical Operations & Admin | 05/22/2019 | 21,797 |
| Wang Theodore T | Director | 05/21/2019 | 26,371 |
| Peacock Jonathan M | Director | 05/21/2019 | 12,198 |
| Tenenbaum Fabian | Chief Executive Officer | 05/21/2019 | 2,975 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 01/23/2019 | 100,000 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 01/23/2019 | 100,000 |
| Wang Theodore T | Director | 01/25/2019 | 315,000 |
| Peacock Jonathan M | Director | 01/25/2019 | 500,000 |
| Amin Naseem | Director | 01/25/2019 | 400,000 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/13/2018 | 89,160 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/17/2018 | 70,944 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/14/2018 | 92,250 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/17/2018 | 70,944 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/14/2018 | 92,250 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/13/2018 | 89,160 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/11/2018 | 228,840 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/10/2018 | 243,640 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/12/2018 | 85,912 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/11/2018 | 228,840 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/10/2018 | 243,640 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/12/2018 | 85,912 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/06/2018 | 42,095 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/05/2018 | 42,325 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/07/2018 | 53,742 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/07/2018 | 53,742 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/06/2018 | 42,095 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 09/05/2018 | 42,325 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 08/16/2018 | 43,109 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 08/15/2018 | 175,902 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 08/14/2018 | 123,868 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 08/14/2018 | 123,868 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 08/16/2018 | 43,109 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 08/15/2018 | 175,902 |
| Quinn Deborah | Chief Medical Officer | 06/12/2018 | 24,982 |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | 06/12/2018 | 16,931 |
| Edmonds Amy | VP Clinical Operations & Admin | 06/12/2018 | 17,773 |
| Tenenbaum Fabian | Chief Executive Officer | 06/12/2018 | 150,462 |
| Fernandes Peter | Chief Regulatory & Safety Offr | 06/12/2018 | 26,790 |
| Dekker Martin | VP of Engineering & Manuf | 06/12/2018 | 17,711 |
| Fernandes Peter | Chief Regulatory & Safety Offr | 01/04/2018 | 87,949 |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | 01/04/2018 | 57,718 |
| Dekker Martin | VP of Engineering & Manuf | 01/04/2018 | 60,467 |
| Quinn Deborah | Chief Medical Officer | 01/04/2018 | 82,454 |
| Schoeps Megan | Principal Financial Officer | 12/13/2017 | 490 |
| Schoeps Megan | Principal Financial Officer | 05/17/2017 | 14,683 |
| Luehring Jens | Director | 12/09/2016 | 11,200 |
| Quinn Deborah | Chief Medical Officer | 09/12/2016 | 25,596 |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | 09/12/2016 | 6,449 |
| Dekker Martin | VP of Device Engineering | 09/12/2016 | 18,400 |
| Edmonds Amy | VP Clinical Operations & Admin | 09/12/2016 | 18,355 |
| Fernandes Peter | Chief Regulatory Officer | 09/12/2016 | 27,303 |
| Peacock Jonathan M | President and CEO | 05/17/2016 | 6,841 |
| Peacock Jonathan M | President and CEO | 12/15/2015 | 20,400 |
| Peacock Jonathan M | President and CEO | 12/16/2015 | 35,336 |
| Peacock Jonathan M | President and CEO | 08/19/2015 | 27,377 |
| MEGLASSON MARTIN | Chief Scientific Officer | 05/20/2015 | 5,981 |
| Peacock Jonathan M | President and CEO | 05/20/2015 | 48,323 |
| ARCH VENTURE FUND VI LP | 10% Owner | 02/19/2015 | 2,551,992 |
| NELSEN ROBERT | Director | 02/19/2015 | 2,551,992 |
| New Mountain Investments II, LLC | 10% Owner | 02/19/2015 | 12,841,992 |
| Weinstein Adam | Director | 02/19/2015 | 12,841,992 |
| Holt Matthew S. | Director | 02/19/2015 | 12,841,992 |
| Linde North America, Inc. | 10% Owner | 02/19/2015 | 4,306,992 |
| Luehring Jens | Director | 02/19/2015 | 4,306,992 |
| Tasse Daniel | Director | 02/19/2015 | 300,000 |
| Heyrman Reinilde | Chief Clinical Dev. Officer | 02/19/2015 | 18,000 |
| MEGLASSON MARTIN | Chief Scientific Officer | 02/19/2015 | 144,000 |
| Naidu Manesh | Chief Business Officer | 02/19/2015 | 18,000 |
| Peacock Jonathan M | President and CEO | 02/19/2015 | 249,600 |
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Load More
Period of Report: 03/31/2022
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2021
0.46%
2Q
06/30/2021
0.49%
3Q
03/31/2021
0.57%
4Q
12/31/2020
22.42%
5Q
09/30/2020
32.06%
6Q
Load More